NovaBridge Biosciences (FRA:0VY)

Market Cap	243.86M +375.9%
Revenue (ttm)	n/a
Net Income	-75.24M
EPS	-0.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	5
Open	2.080
Previous Close	2.160
Day's Range	2.080 - 2.080
52-Week Range	0.695 - 5.600
Beta	n/a
RSI	44.66
Earnings Date	Aug 21, 2026

About NovaBridge Biosciences

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, imp...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 30
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0VY

Financial Performance

Financial numbers in USD